Prothena to Present Preclinical Data for PRX003 at 2016 AAAAI Annual Meeting
DUBLIN, Ireland, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that …